Dimitris Stellas1, Matthias Szabolcs1, Sanjay Koul1, Zhe Li1, Alexander Polyzos1, Constantinos Anagnostopoulos1, Zoe Cournia1, Constantin Tamvakopoulos1, Apostolos Klinakis1, Argiris Efstratiadis2. 1. Biomedical Research Foundation, Academy of Athens, Athens, Greece (DS, AP, CA, ZC, CT, AK, AE); Department of Pathology and Cell Biology (MS) and Division of Hematology/Oncology (SK), Columbia University Medical Center, New York, NY; Regeneron Research Laboratories, Tarrytown, NY (ZL). 2. Biomedical Research Foundation, Academy of Athens, Athens, Greece (DS, AP, CA, ZC, CT, AK, AE); Department of Pathology and Cell Biology (MS) and Division of Hematology/Oncology (SK), Columbia University Medical Center, New York, NY; Regeneron Research Laboratories, Tarrytown, NY (ZL). arg@bioacademy.gr.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDA) is frequently driven by oncogenic KRAS(KRAS*) mutations. We developed a mouse model of KRAS*-induced PDA and, based on genetic results demonstrating that KRAS* tumorigenicity depends on Myc activity, we evaluated the therapeutic potential of an orally administered anti-Myc drug. METHODS: We tested the efficacy of Mycro3, a small-molecule inhibitor of Myc-Max dimerization, in the treatment of mouse PDA (n = 9) and also of xenografts of human pancreatic cancer cell lines (NOD/SCID mice, n = 3-12). Tumor responses to the drug were evaluated by PET/CT imaging, and histological, immunohistochemical, molecular and microarray analyses. The Student's t test was used for differences between groups. All statistical tests were two-sided. RESULTS: Transgenic overexpression of KRAS* in the pancreas resulted in pancreatic intraepithelial neoplasia in two-week old mice, which developed invasive PDA a week later and became moribund at one month. However, this aggressive form of pancreatic tumorigenesis was effectively prevented by genetic ablation of Myc specifically in the pancreas. We then treated moribund, PDA-bearing mice daily with the Mycro3 Myc-inhibitor. The mice survived until killed at two months. PET/CT image analysis (n = 5) demonstrated marked shrinkage of PDA, while immunohistochemical analyses showed an increase in cancer cell apoptosis and reduction in cell proliferation (treated/untreated proliferation index ratio: 0.29, P < .001, n = 3, each group). Tumor growth was also drastically attenuated in Mycro3-treated NOD/SCID mice (n = 12) carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells (eg, mean tumor weight ± SD of treated heterotopic xenografts vs vehicle-treated controls: 15.2±5.8 mg vs 230.2±43.9 mg, P < .001). CONCLUSION: These results provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDA) is frequently driven by oncogenic KRAS(KRAS*) mutations. We developed a mouse model of KRAS*-induced PDA and, based on genetic results demonstrating that KRAS* tumorigenicity depends on Myc activity, we evaluated the therapeutic potential of an orally administered anti-Myc drug. METHODS: We tested the efficacy of Mycro3, a small-molecule inhibitor of Myc-Max dimerization, in the treatment of mousePDA (n = 9) and also of xenografts of humanpancreatic cancer cell lines (NOD/SCIDmice, n = 3-12). Tumor responses to the drug were evaluated by PET/CT imaging, and histological, immunohistochemical, molecular and microarray analyses. The Student's t test was used for differences between groups. All statistical tests were two-sided. RESULTS: Transgenic overexpression of KRAS* in the pancreas resulted in pancreatic intraepithelial neoplasia in two-week old mice, which developed invasive PDA a week later and became moribund at one month. However, this aggressive form of pancreatic tumorigenesis was effectively prevented by genetic ablation of Myc specifically in the pancreas. We then treated moribund, PDA-bearing mice daily with the Mycro3Myc-inhibitor. The mice survived until killed at two months. PET/CT image analysis (n = 5) demonstrated marked shrinkage of PDA, while immunohistochemical analyses showed an increase in cancer cell apoptosis and reduction in cell proliferation (treated/untreated proliferation index ratio: 0.29, P < .001, n = 3, each group). Tumor growth was also drastically attenuated in Mycro3-treated NOD/SCIDmice (n = 12) carrying orthotopic or heterotopic xenografts of humanpancreatic cancer cells (eg, mean tumor weight ± SD of treated heterotopic xenografts vs vehicle-treated controls: 15.2±5.8 mg vs 230.2±43.9 mg, P < .001). CONCLUSION: These results provide strong justification for eventual clinical evaluation of anti-Myc drugs as potential chemotherapeutic agents for the treatment of PDA.
Authors: David Kozono; Jie Li; Masayuki Nitta; Oltea Sampetrean; David Gonda; Deepa S Kushwaha; Dmitry Merzon; Valya Ramakrishnan; Shan Zhu; Kaya Zhu; Hiroko Matsui; Olivier Harismendy; Wei Hua; Ying Mao; Chang-Hyuk Kwon; Hideyuki Saya; Ichiro Nakano; Donald P Pizzo; Scott R VandenBerg; Clark C Chen Journal: Proc Natl Acad Sci U S A Date: 2015-07-09 Impact factor: 11.205
Authors: Gero Doose; Andrea Haake; Stephan H Bernhart; Cristina López; Sujitha Duggimpudi; Franziska Wojciech; Anke K Bergmann; Arndt Borkhardt; Birgit Burkhardt; Alexander Claviez; Lora Dimitrova; Siegfried Haas; Jessica I Hoell; Michael Hummel; Dennis Karsch; Wolfram Klapper; Karsten Kleo; Helene Kretzmer; Markus Kreuz; Ralf Küppers; Chris Lawerenz; Dido Lenze; Markus Loeffler; Luisa Mantovani-Löffler; Peter Möller; German Ott; Julia Richter; Marius Rohde; Philip Rosenstiel; Andreas Rosenwald; Markus Schilhabel; Markus Schneider; Ingrid Scholz; Stephan Stilgenbauer; Hendrik G Stunnenberg; Monika Szczepanowski; Lorenz Trümper; Marc A Weniger; Steve Hoffmann; Reiner Siebert; Ingram Iaccarino Journal: Proc Natl Acad Sci U S A Date: 2015-09-08 Impact factor: 11.205
Authors: Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn Journal: Nat Rev Cancer Date: 2021-06-29 Impact factor: 60.716
Authors: Jun Zhao; Huamin Wang; Cheng-Hui Hsiao; Diana S-L Chow; Eugene J Koay; Yaan Kang; Xiaoxia Wen; Qian Huang; Ying Ma; James A Bankson; Stephen E Ullrich; Willem Overwijk; Anirban Maitra; David Piwnica-Worms; Jason B Fleming; Chun Li Journal: Biomaterials Date: 2018-01-09 Impact factor: 12.479